Xu, R.; Hoess, C.; Swiercz, J. M.; Brandt, D. T.; Lutz, V.; Petersen, N.; Li, R.; Zhao, D.; Oleksy, A.; Creigh-Pulatmen, T.et al.; Trokter, M.; Fedorova, M.; Atzberger, A.; Strandby, R. B.; Olsen, A. A.; Achiam, M. P.; Matthews, D.; Huber, M.; Groene, H.-J.; Offermanns, S.; Worzfeld, T.: A semaphorin-plexin-Rasal1 signaling pathway inhibits gastrin expression and protects against peptic ulcers. SCIENCE TRANSLATIONAL MEDICINE 14 (654), eabf1922 (2022)
Researchers at the Max Planck Institute develop a new pharmacological approach that specifically targets receptor interactions – with implications for immune defense and blood pressure regulation
A team of researchers at the Max Planck Institute for Heart and Lung Research, led by Prof. Dr. Didier Y.R. Stainier, has been awarded a prestigious ERC Proof of Concept (PoC) grant to advance a groundbreaking RNA-based therapeutic strategy for Duchenne Muscular Dystrophy (DMD).